CB1 receptor positive allosteric modulator unexpectedly antagonized opioid pain relief in morphine-withdrawn rats
A positive allosteric modulator of CB1 receptors (GAT211) antagonized rather than enhanced opioid pain relief in the periaqueductal gray of morphine-withdrawn rats, challenging the expected cannabinoid-opioid synergy.
Quick Facts
What This Study Found
Intra-PAG DAMGO (opioid agonist) dose-dependently reversed morphine-induced hyperalgesia. GAT211 (CB1 PAM) alone did not affect nociception. When co-administered, GAT211 antagonized DAMGO's pain-relieving effects in morphine-withdrawn rats. Electrophysiology showed GAT211 attenuated DAMGO-induced suppression of synaptic inhibition in vlPAG neurons.
Key Numbers
DAMGO dose-dependently reversed hyperalgesia. GAT211 alone had no effect on nociception. Co-administration: GAT211 antagonized DAMGO in morphine-withdrawn rats. Electrophysiology confirmed GAT211 blocked DAMGO's synaptic effects via CB1R.
How They Did This
Rats chronically treated with morphine or saline received intra-PAG injections of DAMGO (opioid agonist), GAT211 (CB1 PAM), or both. Thermal nociception measured. Slice electrophysiology examined synaptic transmission in the ventrolateral PAG.
Why This Research Matters
Cannabinoid-opioid combinations are being explored for pain management. This finding that a CB1 positive allosteric modulator can antagonize opioid effects in certain contexts adds important complexity to this therapeutic strategy.
The Bigger Picture
The assumption that enhancing cannabinoid signaling always synergizes with opioids may not hold in all contexts, particularly in opioid-dependent states, with implications for pain management strategies.
What This Study Doesn't Tell Us
Single brain region examined (PAG); morphine-withdrawn state may not represent all clinical contexts; GAT211 is one specific CB1 PAM and results may not generalize to others.
Questions This Raises
- ?Is this antagonism specific to the withdrawal state, or would it occur in opioid-naive contexts?
- ?Could different CB1 PAMs have different interactions with opioids?
Trust & Context
- Key Stat:
- CB1 positive allosteric modulation antagonized rather than enhanced opioid analgesia
- Evidence Grade:
- Single animal study with both behavioral and electrophysiological data, but limited to one brain region and one CB1 PAM.
- Study Age:
- Published in 2020.
- Original Title:
- Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
- Published In:
- Psychopharmacology, 237(12), 3729-3739 (2020)
- Database ID:
- RTHC-02495
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Doesn't combining cannabinoids with opioids usually help pain?
Some evidence suggests cannabinoid-opioid synergy for pain, but this study found the opposite in morphine-withdrawn rats: enhancing CB1 signaling via a positive allosteric modulator actually blocked opioid pain relief. This suggests the interaction may depend on opioid exposure history.
What is a positive allosteric modulator?
A PAM enhances the receptor's response to its natural ligands without directly activating it. For CB1, this means boosting the effects of endocannabinoids rather than adding an external agonist like THC. PAMs were expected to avoid some side effects of direct agonists.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-painkillers-opioid-interactions
- thc-and-muscle-relaxers-combining
- thc-and-ibuprofen-safe-combine-research
Cite This Study
https://rethinkthc.com/research/RTHC-02495APA
Datta, Udita; Kelley, Leslie K; Middleton, Jason W; Gilpin, Nicholas W. (2020). Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.. Psychopharmacology, 237(12), 3729-3739. https://doi.org/10.1007/s00213-020-05650-5
MLA
Datta, Udita, et al. "Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.." Psychopharmacology, 2020. https://doi.org/10.1007/s00213-020-05650-5
RethinkTHC
RethinkTHC Research Database. "Positive allosteric modulation of the cannabinoid type-1 rec..." RTHC-02495. Retrieved from https://rethinkthc.com/research/datta-2020-positive-allosteric-modulation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.